Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
2
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?
5